Lifecare ASA

Lifecare ASA: Key information relating to the consolidation (reverse split) of shares and warrants

Reference is made to the extraordinary general meeting of the Company held on

17 September 2024, where it was resolved to consolidate the Company's shares.

Reference is further made to the warrants issued by the Company pursuant to a

resolution by the extraordinary general meeting of the Company held on 16 May

2024 (the "Warrants"). Pursuant to their terms, the Warrants shall be

consolidated in the same ratio as the shares. The following key information is

provided in connection with the consolidation (reverse split) of the shares

and Warrants:

Date on which the corporate action was made public: 17 September 2024.

Consolidation ratio for shares and Warrants: 13 old shares give 1 new share /

13 old Warrants give 1 new Warrant.

Last day including right: 30 September 2024.

Ex-date: 1 October 2024.

Record date: 2 October 2024.

Date of approval: 17 September 2024 (EGM date).

Other information: A new ISIN number will be issued for the shares. Further

information will be provided in a separate stock exchange announcement. The

Warrants will retain the same ISIN as used today.

This information is published in accordance with the requirements of the

Continuing Obligations.

About Lifecare:

Lifecare is a clinical stage medical sensor company developing technology for

sensing and monitoring of various body analytes. Lifecare's main focus is to

bring the next generation of Continuous Glucose Monitoring ("CGM") systems to

market. Lifecare enables osmotic pressure as sensing principle, combined with

the ability to manipulate Nano-granular Tunnelling Resistive sensors ("NTR")

on the sensor body for read-out of pressure variations. Lifecare's sensor

technology is referred to as "Sencell" and is suitable for identifying and

monitoring the occurrence of a wide range of analytes and molecules in the

human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, [email protected], +47 40 05 90 40

Renete Kaarvik, CFO, [email protected], +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities

Trading Act, §5-12. The information was submitted for publication at

2024-09-26 07:00 CEST.

AI Terminal